UTHR - United Therapeutics Non-GAAP EPS of $3.51 misses by $0.54 revenue of $415.2M misses by $12.39M
United Therapeutics press release (NASDAQ:UTHR): Q4 Non-GAAP EPS of $3.51 misses by $0.54. Revenue of $415.2M (+7.9% Y/Y) misses by $12.39M. Company reaffirms target to reach 6,000 patients with Tyvaso by the end of 2022 Double-digit percentage revenue and patient count growth in full-year 2021
For further details see:
United Therapeutics Non-GAAP EPS of $3.51 misses by $0.54, revenue of $415.2M misses by $12.39M